Key facts
- ImYoo’s last known valuation is $7.1M (Jun 2022).
- It has raised $4.1M; the latest was Accelerator/Incubator in Mar 2026.
- Notable investors include Plug and Play Tech Center, Boost VC, Arben Ventures, California Institute of Technology Endowment, Corundum Systems Biology — 11 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 11 names
- ·Watchlist + deal alerts for ImYoo
- ·The full record, as it builds
Funding rounds
No funding rounds for ImYoo are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ImYoo
Developer of a patient-enabled biodiscovery platform intended to generate scalable, high-fidelity, longitudinal data. The company's platform brings single-cell multi-omic analysis to small blood volumes self-collected at home to better understand disease complexities and develop precision diagnostics and therapies, enabling users to identify critical markers from longitudinal samples and during key disease events, like autoimmune flares or adverse therapeutic side effects.
- Sector
- Healthcare
- HQ
- Mountain View, CA, United States
- Founded
- 2021
- Employees
- 5
- Website
- imyoo.health/
- Ownership
- Privately Held (backing)
ImYoo doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ImYoo shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ImYoo in its N-PORT filings yet. We sweep new filings monthly.